Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 16

  • 497 clinical trials
  • 183 recruiting
  • 211 conditions
  • 25 countries

Conditions in this area

211 conditions with trials, the busiest first

Type 2 diabetes mellitus83Type 1 diabetes mellitus38Endocrine ophthalmopathy26Neuroblastoma26Obesity22Diabetes mellitus21Neuroendocrine tumour19Gastroenteropancreatic neuroendocrine tumour disease16Overweight16Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Chronic kidney disease8Adrenoleukodystrophy7Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+187

Clinical trials in Endocrine disorders

497 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

497 clinical trials

Neuroendocrine carcinoma

Recruiting

Study Comparing FOLFIRINOX and Cisplatin-Etoposide for Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Turner's syndrome

Recruiting

Study on Estrogen Treatment (Oral vs. Transdermal) for Women with Turner Syndrome

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Estradiol
  • Sponsor:Region Midtjylland

Diminished ovarian reserve

Recruiting

Study on the Safety and Effectiveness of Platelet Concentrate for Women with Low Ovarian Reserve

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Platelet Concentrate
  • Sponsor:Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

Pituitary-dependent Cushing's syndrome

Not yet recruiting

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ATUMELNANT
  • Sponsor:Crinetics Pharmaceuticals Inc.

Type 2 diabetes mellitus+2

Not yet recruiting

Efficacy and Safety of Olatorepatide in Adults with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Regeneron Pharmaceuticals Inc.

Diabetes mellitus+2

Not yet recruiting

A Phase III Study of ASC30 Sodium for Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus

Not yet recruiting

Efficacy and Safety of Alogliptin Plus Empagliflozin Compared with Alogliptin Alone or Empagliflozin Alone in Adults with Type 2 Diabetes on Metformin

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alogliptin
  • Sponsor:Tecnimede-Sociedade Tecnico-Medicinal S.A.

Gastrointestinal neuroendocrine tumour

Not yet recruiting

Study of Lutetium-177 and Yttrium-90 DOTATATE combination therapy for patients with inoperable gastrointestinal neuroendocrine tumors

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dotatate
  • Sponsor:Narodowe Centrum Badan Jadrowych

Type 2 diabetes mellitus+4

Not yet recruiting

Effect of semaglutide on weight loss and metabolic control in liver transplant candidates with obesity

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia

Type 2 diabetes mellitus

Not yet recruiting

Phase 3 Study of Oral Orforglipron vs Weekly Dulaglutide in Children and Adolescents (10‑<18 years) with Type 2 Diabetes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Type 2 diabetes mellitus+2

Not yet recruiting

Study of AZD6234 (lenbelintide) Added to Incretin Therapy in Adults with Obesity or Overweight and a Weight‑Related Comorbidity, With or Without Type 2 Diabetes

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide46 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsSodium Chloride13 clinical trialsCisplatin12 clinical trialsEtoposide12 clinical trialsMetformin Hydrochloride12 clinical trialsCarboplatin11 clinical trialsInsulin Glargine11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.